{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:22:58Z","timestamp":1788841378031,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.autrev.2020.102671","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T22:31:10Z","timestamp":1600122670000},"page":"102671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?"],"prefix":"10.1016","volume":"19","author":[{"given":"Philipp","family":"Gauckler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Crnogorac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Delbarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kresimir","family":"Galesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u00e2n","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Hru\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir Singh","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth J.","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Segelmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Zonozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"10032","key":"10.1016\/j.autrev.2020.102671_bb0010","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","article-title":"Primary glomerulonephritides","volume":"387","author":"Floege","year":"2016","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2215\/CJN.01920219","article-title":"Management of Adult Minimal Change Disease","volume":"14","author":"Korbet","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0030","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal Segmental Glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0040","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.ajkd.2015.04.007","article-title":"AJKD atlas of renal pathology: focal segmental glomerulosclerosis","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfu035","article-title":"Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist","volume":"30","author":"Sethi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl_1","key":"10.1016\/j.autrev.2020.102671_bb0050","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfw324","article-title":"What are we missing in the clinical trials of focal segmental glomerulosclerosis?","volume":"32","author":"Zand","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/14.3.550","article-title":"The diagnostic trash bin of focal and segmental glomerulosclerosis--an effort to provide rational clinical guidelines","volume":"14","author":"Schmidt","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/kisup.2012.19","article-title":"Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0065","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Toronto glomerulonephritis registry G. focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.autrev.2020.102671_bb0080","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis","volume":"5","author":"McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0085","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/ndt\/gfu355","article-title":"Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future","volume":"29","author":"Maas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000167173","article-title":"Recurrent focal segmental glomerulosclerosis. A pathological study of the early lesion","volume":"6","author":"Verani","year":"1986","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2020.102671_bb0095","doi-asserted-by":"crossref","first-page":"2068691","DOI":"10.1155\/2016\/2068691","article-title":"Soluble Urokinase receptors in focal segmental glomerulosclerosis: a review on the scientific point of view","volume":"2016","author":"Kronbichler","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2020.102671_bb0100","doi-asserted-by":"crossref","first-page":"3765608","DOI":"10.1155\/2016\/3765608","article-title":"Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates","volume":"2016","author":"Konigshausen","year":"2016","journal-title":"Biomed Res Int"},{"issue":"7880","key":"10.1016\/j.autrev.2020.102671_bb0105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0110","first-page":"37","article-title":"A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome","volume":"23","author":"Lagrue","year":"1975","journal-title":"Biomedicine."},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0115","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1681\/ASN.2006070710","article-title":"Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats","volume":"18","author":"Lai","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0120","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1994.171","article-title":"IL-8 production by peripheral blood mononuclear cells in nephrotic patients","volume":"45","author":"Garin","year":"1994","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0125","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1046\/j.1523-1755.2000.00996.x","article-title":"Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin","volume":"57","author":"Cheung","year":"2000","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nm.2261","article-title":"Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome","volume":"17","author":"Clement","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1042\/CS20040095","article-title":"Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome","volume":"107","author":"van den Berg","year":"2004","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"10.1016\/j.autrev.2020.102671_bb0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/adc.56.7.509","article-title":"Steroid-responsive and nephrotic syndrome and allergy: clinical studies","volume":"56","author":"Meadow","year":"1981","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.autrev.2020.102671_bb0145","first-page":"S147","article-title":"Food allergy and idiopathic nephrotic syndrome","volume":"27","author":"Lagrue","year":"1989","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2188\/jea.JE20140167","article-title":"Occurrence of common allergic diseases in children with idiopathic nephrotic syndrome","volume":"25","author":"Wei","year":"2015","journal-title":"J Epidemiol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0155","first-page":"298","article-title":"T helper 1 and T helper 2 cytokines in atopic children with steroid-sensitive nephrotic syndrome","volume":"9","author":"Youssef","year":"2015","journal-title":"Iran J Kidney Dis"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","article-title":"Idiopathic nephrotic syndrome and atopy: is there a common link?","volume":"54","author":"Abdel-Hafez","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1651-2227.2007.00154.x","article-title":"Atopy in childhood idiopathic nephrotic syndrome","volume":"96","author":"Salsano","year":"2007","journal-title":"Acta Paediatr"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00467-004-1438-8","article-title":"Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome","volume":"19","author":"Cheung","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120529","article-title":"Eosinophilia and kidney disease: more than just an incidental finding?","volume":"7","author":"Gauckler","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2020.102671_bb0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","article-title":"Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice","volume":"89","author":"Jamin","year":"2018","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.autrev.2020.102671_bb0185","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00467-010-1507-0","article-title":"Characterisation of renal immune cell infiltrates in children with nephrotic syndrome","volume":"25","author":"Benz","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"21","key":"10.1016\/j.autrev.2020.102671_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.81836","article-title":"B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement","volume":"2","author":"Kim","year":"2017","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.autrev.2020.102671_bb0195","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJM199712113372412","article-title":"Interleukin-4 and the genetics of atopy","volume":"337","author":"Rosenwasser","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0200","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00467-010-1676-x","article-title":"Minimal change disease: a \u201ctwo-hit\u201d podocyte immune disorder?","volume":"26","author":"Shimada","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.autrev.2020.102671_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","article-title":"NEPHRUTIX: a randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome","volume":"88","author":"Boumediene","year":"2018","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.autrev.2020.102671_bb0210","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1681\/ASN.2014030247","article-title":"HLA-DQA1 and PLCG2 are candidate risk loci for childhood-onset steroid-sensitive nephrotic syndrome","volume":"26","author":"Gbadegesin","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102671_bb0215","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1681\/ASN.2017111185","article-title":"Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome","volume":"29","author":"Debiec","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102671_bb0220","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1681\/ASN.2018101054","article-title":"Genetic identification of two novel loci associated with steroid-sensitive nephrotic syndrome","volume":"30","author":"Dufek","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.autrev.2020.102671_bb0225","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","article-title":"Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives","volume":"9","author":"Bezombes","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0230","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0235","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood."},{"issue":"85","key":"10.1016\/j.autrev.2020.102671_bb0240","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0245","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1097\/TP.0000000000002008","article-title":"Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis Postkidney transplantation","volume":"102","author":"Alasfar","year":"2018","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0250","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1681\/ASN.2015060672","article-title":"Kruppel-like factor 15 mediates glucocorticoid-induced restoration of podocyte differentiation markers","volume":"28","author":"Mallipattu","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/kisup.2012.18","article-title":"Chapter 5: Minimal-change disease in adults","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0260","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/kisup.2012.15","article-title":"Chapter 2: General principles in the management of glomerular disease","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0265","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/kisup.2012.16","article-title":"Chapter 3: Steroid-sensitive nephrotic syndrome in children","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0270","doi-asserted-by":"crossref","first-page":"c75","DOI":"10.1159\/000093993","article-title":"Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study","volume":"104","author":"Goumenos","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.autrev.2020.102671_bb0275","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/IJNRD.S126844","article-title":"Optimal management of primary focal segmental glomerulosclerosis in adults","volume":"10","author":"Beaudreuil","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0280","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.semnephrol.2016.09.007","article-title":"Clinical trials in FSGS: past challenges and new trial designs","volume":"36","author":"Gipson","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.autrev.2020.102671_bb0285","doi-asserted-by":"crossref","first-page":"4192578","DOI":"10.1155\/2016\/4192578","article-title":"Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades","volume":"2016","author":"Beer","year":"2016","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0290","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","article-title":"Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?","volume":"34","author":"Ponticelli","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0295","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0300","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000495352","article-title":"Short-term steroid regimen for adult steroid-sensitive minimal change disease","volume":"49","author":"Ozeki","year":"2019","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0305","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0310","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.krcp.2012.04.321","article-title":"Complete remission induced by tacrolimus and low-dose prednisolone in adult minimal change nephrotic syndrome: a pilot study","volume":"31","author":"Kim","year":"2012","journal-title":"Kidney Res Clin Pract"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0315","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/ndt\/8.12.1326","article-title":"Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial","volume":"8","author":"Ponticelli","year":"1993","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0320","first-page":"143","article-title":"Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults","volume":"55","author":"Matsumoto","year":"2001","journal-title":"Clin Nephrol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102671_bb0325","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2169\/internalmedicine.43.668","article-title":"Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome","volume":"43","author":"Matsumoto","year":"2004","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0330","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.clinthera.2012.03.008","article-title":"Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial","volume":"34","author":"Li","year":"2012","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0335","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/ndt\/gfm637","article-title":"Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome","volume":"23","author":"Li","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0340","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.kint.2018.07.021","article-title":"An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN study)","volume":"94","author":"Remy","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0345","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America nephrotic syndrome study group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0350","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1093\/ndt\/gfh536","article-title":"Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy","volume":"19","author":"Duncan","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.autrev.2020.102671_bb0355","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.autrev.2020.102671_bb0360","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ki.2011.191","article-title":"Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial","volume":"80","author":"Deegens","year":"2011","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0365","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study","volume":"23","author":"Senthil Nayagam","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.ajkd.2003.09.027","article-title":"Cyclosporine a and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis","volume":"43","author":"Heering","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0375","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000346256","article-title":"Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial","volume":"37","author":"Ren","year":"2013","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0380","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.V541049","article-title":"Cyclosporine in the treatment of idiopathic nephrosis","volume":"5","author":"Niaudet","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102671_bb0385","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","article-title":"Does cyclophosphamide still play a role in glomerular diseases?","volume":"17","author":"Ponticelli","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0390","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2020.102671_bb0395","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion."},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0400","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","article-title":"Rituximab for immunologic renal disease: what the nephrologist needs to know","volume":"16","author":"Kronbichler","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0405","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"issue":"20","key":"10.1016\/j.autrev.2020.102671_bb0410","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.autrev.2020.102671_bb0415","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0420","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0425","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0430","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0435","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0440","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2020.102671_bb0445","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2215\/CJN.01600214","article-title":"Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis","volume":"9","author":"Hogan","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102671_bb0450","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0455","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11255-012-0206-0","article-title":"Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature","volume":"45","author":"Kong","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0460","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0465","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0470","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40259-017-0221-x","article-title":"Rituximab for steroid-dependent or frequently relapsing idiopathic nephrotic syndrome in adults: a retrospective, multicenter study in Spain","volume":"31","author":"DaSilva","year":"2017","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.autrev.2020.102671_bb0475","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","article-title":"Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance","volume":"29","author":"Guitard","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.autrev.2020.102671_bb0480","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477944","article-title":"High-dose rituximab ineffective for focal segmental glomerulosclerosis: a long-term observation study","volume":"46","author":"Roccatello","year":"2017","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1016\/j.autrev.2020.102671_bb0485","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0490","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/nep.13554","article-title":"Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy","volume":"24","author":"Ramachandran","year":"2019","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0495","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00467-012-2361-z","article-title":"Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?","volume":"28","author":"Delbe-Bertin","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0500","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5414\/CN108835","article-title":"Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome","volume":"85","author":"Fujinaga","year":"2016","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0505","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2020.102671_bb0510","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0515","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2020.102671_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030298","article-title":"Outcomes of older patients (>\/=60 years) with new-onset idiopathic nephrotic syndrome receiving immunosuppressive regimen: a multicentre study of 116 patients","author":"Colliou","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0525","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","article-title":"Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults","volume":"28","author":"Takei","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0530","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.autrev.2020.102671_bb0535","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0540","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0545","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102671_bb0550","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102671_bb0555","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1002\/art.34560","article-title":"Rituximab mediates loss of CD19 on B cells in the absence of cell death","volume":"64","author":"Jones","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2020.102671_bb0560","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","article-title":"Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion","volume":"22","author":"Sato","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102671_bb0565","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0570","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","article-title":"Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome","volume":"84","author":"Bhatia","year":"2018","journal-title":"Pediatr Res"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0575","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","article-title":"Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment","volume":"21","author":"Fujinaga","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102671_bb0580","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"JASN"},{"issue":"4","key":"10.1016\/j.autrev.2020.102671_bb0585","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000360908","article-title":"Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review","volume":"39","author":"Kronbichler","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2020.102671_bb0590","doi-asserted-by":"crossref","first-page":"7689254","DOI":"10.1155\/2017\/7689254","article-title":"Recent treatment advances and new trials in adult nephrotic syndrome","volume":"2017","author":"Konigshausen","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2020.102671_bb0595","article-title":"Rituximab in minimal change disease and focal segmental glomerulosclerosis","volume":"gfz205","author":"Kronbichler","year":"2019","journal-title":"Nephrol Dial Transplant"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:17:52Z","timestamp":1761599872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220302469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":119,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1568997220302469"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102671","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102671"}}